IVIG for anti-HMGCR muscle disease
Part of Bones, joints & muscles, Immune system & allergy clinical trials.
This trial tests if IVIG (intravenous immunoglobulin, a donated blood product that helps the immune system) can improve muscle strength and reduce damage in people with anti-HMGCR immune-mediated necrotizing myopathy (a rare muscle disease where the immune system attacks muscle cells). It may help you if your muscle weakness is not too severe and you haven't tried IVIG before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 16 years old
- You have a positive anti-HMGCR antibody test (a blood marker for this muscle disease)
- Your muscle strength (measured by a special test) is below 142 out of 160
- Your creatine kinase (CK) level, a sign of muscle damage, is more than 5 times the normal limit
- You have had this muscle disease for less than 3 years
- You live in a state where the study takes place
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational medication called ublituximab (an infusion) for people with a rare autoimmune muscle disease called IMNM. It aims to reduce muscle weakness and damage by targeting specific immune cells (B cells). To join, you need a recent diagnosis (within 1 year), specific antibodies, and be on limited other medications.
This trial tests a new cell therapy (GC012F) for people with idiopathic inflammatory myopathy (IIM) that hasn't responded to standard treatments. It aims to see if this treatment can help control muscle inflammation and weakness.
This trial tests a new type of cell therapy (BCMA-CD19 cCAR-T) for people with inflammatory myopathy that hasn't improved with standard treatments. The goal is to see if this treatment can help control the disease.
This study tests a medication called efgartigimod for people with myasthenia gravis who need regular IVIG treatments. The goal is to see if efgartigimod can help reduce the need for IVIG.
This trial tests whether a combination of steroid medicine (corticosteroid) and a targeted immune drug (rituximab) can prevent mild eye-muscle weakness from spreading to other muscles. It is for people newly diagnosed with ocular myasthenia who have not yet taken immune-suppressing treatments.
This trial is testing a new CAR-T cell treatment (Eque-cel) for people with a rare muscle disease called immune-mediated necrotizing myopathy that hasn't improved with standard treatments. The treatment aims to stop the immune system from attacking the muscles.
Hear when a new Anti-3-hydroxy-3-methylglutaryl-CoA Reductase (HMGCR) Immune-Mediated Necrotizing Myopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.